Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

ABSTRACT:

Background

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the mainstay for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). While the approved CDK4/6i have demonstrated significant improvements in progression-free survival (PFS), inconsistencies exist for overall survival (OS) benefits. Here, we report updated efficacy results from PARSIFAL, a randomized phase II study, that evaluated first-line palbociclib with either letrozole or fulvestrant in postmenopausal patients with endocrine-sensitive, HR-positive/HER2-negative ABC.

Patients and methods

PARSIFAL-LONG was an international, multicenter, observational study that extended follow-up for patients included in PARSIFAL. The primary objective eva

SUBMITTER: Llombart-Cussac A 

PROVIDER: S-EPMC12212146 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature